How to Help Your Patients Find Insulin Glargine-Yfgn in Stock: A Provider's Guide

For prescribers managing patients with Type 1 or Type 2 diabetes, the discontinuation of Semglee (insulin glargine-yfgn) has created an unexpected layer of clinical and administrative work. Patients who were stable on Semglee are now facing pharmacy dead-ends, insurance coverage gaps, and product confusion. This guide provides practical, actionable workflows your practice can implement immediately to help patients maintain uninterrupted access to their basal insulin.

Understanding the Current Access Landscape

Semglee was discontinued December 31, 2025 by Biocon Biologics. As of 2026, the insulin glargine-yfgn access landscape looks like this:

Available products: Civica Rx unbranded insulin glargine-yfgn pens ($45/5 pens), Winthrop generic vials/pens, Lantus (interchangeable), Basaglar, Rezvoglar.

Interchangeability: Pharmacists can still substitute Lantus for insulin glargine-yfgn (and vice versa) without a new prescription. This applies to Civica Rx's unbranded version as well.

Non-interchangeable alternatives: Basaglar, Rezvoglar, Toujeo, Levemir, and Tresiba require a new prescription.

Workflow 1: Identify Semglee Patients in Your Panel

The first step is knowing which patients are affected. If your EHR has medication management or prescribing history, run a report for all active patients with prescriptions for:

Semglee (brand)

Insulin glargine-yfgn (generic name)

For patients still listed as Semglee, update prescriptions to insulin glargine-yfgn (unbranded) or Lantus, and document the Semglee discontinuation in the medical record. This preempts confusion at the pharmacy.

Workflow 2: Writing Prescriptions for Maximum Access

When writing or renewing basal insulin prescriptions in 2026, consider the following:

Write for 'insulin glargine-yfgn' generically to allow pharmacist flexibility to use Civica Rx or other available versions.

Consider adding 'or interchangeable product including Lantus (insulin glargine)' to the prescription notes for maximum pharmacy flexibility.

For patients where cost is the priority, specifically request Civica Rx insulin glargine-yfgn ($45/5 pens) and verify if their pharmacy carries it.

If writing for Basaglar, Rezvoglar, Toujeo, or Tresiba, ensure these are written as distinct prescriptions — they are not interchangeable with glargine-yfgn and require specific clinical authorization.

Workflow 3: Using medfinder to Find Stock for Patients

medfinder offers a provider-facing tool at medfinder.com/providers that allows your staff to check pharmacy availability for specific medications in a patient's area. Rather than having patients spend hours calling pharmacies, your front office can:

Submit the patient's medication, dosage, and ZIP code.

medfinder calls pharmacies in the area to check stock.

Results are sent directly to the patient via text, including which pharmacies have the drug in stock.

This is particularly valuable for patients with limited mobility, elderly patients, or patients in rural areas where calling multiple pharmacies is a significant barrier.

38,224+ patients found their medications in stock

38K+

Find Insulin Glargine-Yfgn In Stock Today →

Workflow 4: Addressing Formulary and Insurance Gaps

If a patient's insurance no longer covers their insulin glargine product:

Check the payer's current formulary for covered insulin glargine products — many have updated post-Semglee discontinuation.

Submit a prior authorization citing the Semglee discontinuation and medical necessity for continuity of care.

Remind patients about manufacturer savings programs: Sanofi Valyou ($35/month for Lantus), Eli Lilly $35/month for Basaglar, and Civica Rx at $45/5 pens.

For Medicare patients, remind them of the $35/month IRA cap on covered insulin products under Part D.

Sample Language for Patient Communication

Consider sending a brief portal message to affected patients, such as: 'Semglee, the insulin glargine product you have been using, was discontinued on December 31, 2025. Your pharmacy can substitute it with Lantus without a new prescription, since these are interchangeable. If you have any trouble filling your insulin prescription, please contact our office immediately or use medfinder.com to locate pharmacies with stock in your area.'

For the full clinical briefing on the shortage, see: Insulin Glargine-Yfgn Shortage: What Providers Need to Know in 2026.